To AML hematology homepage

AML hematology

Exploring Real-World Cases of Gilteritinib in FLT3-Mutated AML

Explore real-world patient cases demonstrating how gilteritinib, a tyrosine kinase inhibitor (TKI), can be applied in the treatment of R/R FLT3-mutated acute myeloid leukemia (AML).

Through practical examples and expert insights, you’ll discover different approaches to managing relapsed or refractory disease, supported by in-depth articles and video discussions.

Materials

Accessible only to healthcare professionals authorized to prescribe

Clinical Case Study Compendium:

PDF case reports 1 & 2

The impact of gilteritinib in daily practice as salvage treatment and as bridging therapy. Real-World Experiences by Dr. A. de Voeght; Sart Tilman-CHU Liège Part I: first 2 case reports

Accessible only to healthcare professionals authorized to prescribe

Part 2: Clinical Case Study Compendium:

PDF case reports 3 & 4

The impact of gilteritinib in daily practice after intensive chemotherapy and following an allo-HSCT

Accessible only to healthcare professionals authorized to prescribe

Clinical Case Study Compendium:

Video case report 5

Real-World Experiences by prof. dr. M. Beckers, UZ Leuven. Video of case report 5

Accessible only to healthcare professionals authorized to prescribe

Clinical Case Study Compendium:

Video case report 2

Real-World Experiences by Dr. A. de Voeght; Sart Tilman-CHU Liège Video of the 2nd case report

Accessible only to healthcare professionals authorized to prescribe

Clinical Case Study Compendium

Video case report 3

Real-World Experiences by Dr. A. de Voeght; Sart Tilman-CHU Liège Video of the 3rd case report

Accessible only to healthcare professionals authorized to prescribe

Clinical Case Study Compendium:

Video case report 1

Real-World Experiences by Dr. A. de Voeght; Sart Tilman-CHU Liège Video of the 1st case report

AML: Acute Myeloid Leukemia

COPYRIGHT © 2026 ASTELLAS PHARMA B.V. MAT-BE-XOS-2025-00030 - DEC 2025